NCT07413601 2026-02-17
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting